A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older

NCT01222403 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

767

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: Fluad_MF59-adjuvanted trivalent influenza subunit vaccine
BIOLOGICAL: Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine

Sponsor

Novartis Vaccines